NCT05519475招募中2 期
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 120
- 试验地点
- 135
- 主要终点
- Change in qFibrosis
研究概览
简要总结
This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH). MASH is a form of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD). MASH occurs when fat builds up in liver cells, damaging them, and making the liver inflamed and stiff from fibrosis (scar tissue). MASH can progress to cirrhosis (long term scarring) and liver failure (when the liver cannot perform its job). The aim of the study is to see the effect of the study drug on lessening liver scarring related to MASH.
The study is looking at several other research questions, including:
- How ALN-HSD works to improve liver function and lessen MASH-related inflammation in the liver
- What side effects may happen from receiving the study drug
- How much study drug and study drug metabolites (byproduct of the body breaking down the study drug) are in the blood at different times
- Better understanding of the study drug and MASH
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult male or female ≥18 years (or country's legal age of adulthood)
- •A diagnosis of MASH with Fibrosis (F) stage 2 or 3, according to the NASH-CRN
- •NAS score ≥3, as defined in the protocol
- •Meets genotype criteria for study enrollment, as defined in the protocol
- •Has a protocol defined FibroScan®-AST (FAST) score at screening or within approximately 12 weeks of screening
排除标准
- •Evidence of other forms of known chronic liver disease, as defined in the protocol
- •Known history of alcohol or other substance abuse within the last year or at any time during screening, as defined in the protocol
- •History of Type 1 diabetes
- •Bariatric surgery within approximately 5 years prior to or planned during the study period
- •Prior exposure to any investigational drug targeting HSD17B13 or patatin-like phospholipase domain containing 3 (PNPLA3) (eg, ALN-HSD, ARO-HSD, ALN-PNP, AZD2693)
- •Note: Other protocol-defined Inclusion/Exclusion Criteria apply
研究组 & 干预措施
Placebo
Placebo Comparator
Randomized 1:1
干预措施: Placebo (Drug)
ALN-HSD
Experimental
Randomized 1:1
干预措施: ALN-HSD (Drug)
结局指标
主要结局
Change in qFibrosis
时间窗: Baseline to week 52
Change in the continuous quantitative liver fibrosis (qFibrosis) score measured by second harmonic generation/two-photon excitation microscopy
次要结局
- Change in enhanced liver fibrosis (ELF)(Baseline to week 52)
- Change in serum aspartate aminotransferase (AST)(Baseline to week 52)
- Improvement of non-alcoholic steatohepatitis clinical research network (NASH-CRN) fibrosis (F) stage by ≥1 stage without worsening of MASH on liver biopsy(Baseline to week 52)
- Resolution of MASH with no worsening of NASH-CRN fibrosis on liver biopsy(Baseline to week 52)
- Change in serum alanine aminotransferase (ALT)(Baseline to week 52)
- Change in N-terminal type III collagen propeptide (PRO-C3)(Baseline to week 52)
- Change in NIS4, a non-invasive fibrosis biomarker of NASH(Baseline to week 52)
- Change in Fibrosis-4 (FIB-4)(Baseline to week 52)
- Change in hepatic hydroxysteroid 17β dehydrogenase 13 (HSD17B13) transcript level(Baseline to week 52)
- Incidence of progression in qFibrosis on liver biopsy(Baseline to week 52)
- Incidence of treatment-emergent adverse events (TEAEs)(Baseline to week 84)
- Severity of treatment-emergent adverse events (TEAEs)(Baseline to week 84)
研究者
研究点 (135)
Loading locations...
相似试验
进行中（未招募）
1 期
A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy AdultsNCT06452771Regeneron Pharmaceuticals59
招募中
1 期
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Healthy VolunteersMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)NCT05648214Regeneron Pharmaceuticals172
进行中（未招募）
1 期
Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy AdultsHealthy VolunteerNCT06669234Regeneron Pharmaceuticals56
已完成
1 期
A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk FactorNonalcoholic Fatty Liver Disease (NAFLD)Nonalcoholic Steatohepatitis (NASH)Genetic Risk FactorNCT06024408Regeneron Pharmaceuticals9
已完成
1 期
Single and Multiple Ascending Oral Dose Study of RX-10001 in Healthy VolunteersHealthyNCT00941018Resolvyx Pharmaceuticals, Inc56